International Journal of Clinical and Laboratory Research

, Volume 23, Issue 1, pp 34–37

Soluble interleukin-2 receptor in hairy-cell leukemia: a reliable marker of disease

  • Achille Ambrosetti
  • Gianpaolo Nadali
  • Fabrizio Vinante
  • Maria Maddalena Ricetti
  • Giuseppe Todeschini
  • Lorella Morosato
  • Donata de Sabata
  • Ivo Andrea Bergamo Andreis
  • Marco Chilosi
  • Gianpietro Semenzato
  • Giovanni Pizzolo
Originals

DOI: 10.1007/BF02592278

Cite this article as:
Ambrosetti, A., Nadali, G., Vinante, F. et al. Int J Clin Lab Res (1993) 23: 34. doi:10.1007/BF02592278

Summary

The CD25 molecule, which corresponds to the p55 α chain of the interleukin-2 receptors, is strongly expressed by neoplastic cells in hairy-cell leukemia and is released in large amounts in the soluble form which is detectable in serum. In order to assess the reliability of the soluble interleukin-2 receptor as a disease marker in the management of patients with hairy-cell leukemia, we investigated serum levels in 35 untreated patients and in 2 patients with the hairy-cell leukemia variant. In 21 of 35 patients soluble receptor levels were also monitored during and after recombinant interferon-α therapy. Clinical and hematological parameters were also assessed. Soluble interleukin-2 receptor levels were extremely high at the time of diagnosis in patients with typical hairy-cell leukemia [32,722±27,001 vs. 331±145 units/ml in controls (mean±SD)], but not in patients with the leukemia variant. A progressive decrease in soluble interleukin-2 receptor levels paralleled the clinical response to treatment, although normal values were never detected, even in patients who achieved an apparent complete remission. After recombinant interferon-α discontinuation, disease recurrence was accompanied by a progressive increase to pre-treatment soluble receptor levels. Overall, a close correlation was found between soluble interleukin-2 receptor values and total tumor burden (r=0.84,P<0.001). On the basis of these data, soluble interleukin-2 receptor should be regarded as a key marker in the management of patients with hairy-cell leukemia.

Key words

Hairy-cell leukemiaSoluble interleukin-2 receptorMinimal residual disease

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Achille Ambrosetti
    • 1
  • Gianpaolo Nadali
    • 1
  • Fabrizio Vinante
    • 1
  • Maria Maddalena Ricetti
    • 1
  • Giuseppe Todeschini
    • 1
  • Lorella Morosato
    • 1
  • Donata de Sabata
    • 1
  • Ivo Andrea Bergamo Andreis
    • 2
  • Marco Chilosi
    • 3
  • Gianpietro Semenzato
    • 4
  • Giovanni Pizzolo
    • 1
  1. 1.Department of HematologyVerona University School of MedicineVeronaItaly
  2. 2.Department of RadiologyVerona University School of MedicineVeronaItaly
  3. 3.Department of PathologyVerona University School of MedicineVeronaItaly
  4. 4.Department of Clinical Medicine, First Medical ClinicPadua University School of MedicinePaduaItaly
  5. 5.Cattedra di EmatologiaPoliclinico Borgo RomaVeronaItaly